A request to test again can mean several different things. Repeating an instrument reading, preparing another portion of the original sample and collecting new units from a batch change different parts of the evidence. A useful investigation specifies which action is intended and what question it can answer.
Name the material used in the follow-up
FDA’s OOS guidance distinguishes retesting original homogeneous sample material from resampling additional units or a newly collected batch sample. That pharmaceutical definition helps prevent an ambiguous request for another test from concealing a change of material.FDA — Investigating Out-of-Specification Test Results for Pharmaceutical Production (opens in a new tab)
| Action | What changes |
|---|---|
| Reinject a prepared solution | The instrument reading is repeated |
| Prepare another original-sample portion | Preparation and measurement are repeated |
| Select another original unit | The material unit also changes |
| Collect a new batch sample | The sampling event changes |
The table describes levels of follow-up, not a mandatory sequence. The appropriate choice depends on the proposed cause and on whether suitable original material remains available.
Use sample and preparation identifiers so readers can distinguish these actions in the final report. The word duplicate alone does not establish what was duplicated.
Match the action to the suspected problem
Consider an original example in which an unexpectedly low result may reflect an incorrect preparation volume. Reinjecting the same solution leaves that volume error in place. It can examine injection behaviour, but it does not independently reproduce the original preparation.
A new preparation from appropriate original material can address a different question. It still needs a documented comparison: how were the amounts and volumes recorded, and does the evidence support the proposed error?
If the concern is that the original selected vial was atypical, collecting other units adds information about the lot. Those units do not reveal the original vial’s true content automatically. Both a low original unit and typical later units could be real.
A later pass does not invalidate the earlier result
FDA warns against repeated testing to obtain a passing outcome and states that passing retests do not provide a scientific basis for invalidating an initial OOS result when no causative error is identified.FDA — Investigating Out-of-Specification Test Results for Pharmaceutical Production (opens in a new tab)
For an original case, a low result from unit A and a passing result from unit B may indicate unit variation, analytical variation or both. Calling B the replacement result hides the fact that two different units were measured.
If a documented error is found, explain how it affected A and which corrected or additional result addresses that error. If no cause is found, preserve the disagreement as part of the evidence.
Selecting the best result, averaging until the number falls within a limit or stopping only when a preferred outcome appears changes the decision process. Those choices need a scientific rationale established independently of the desired result.
Make the investigation reproducible on paper
A clear plan names the hypothesis, material available, proposed comparisons, number of follow-ups and how all outcomes will be interpreted. It also identifies what the work cannot establish if the original sample has been consumed or changed.
The final account should link each value to its unit, preparation and method. Record why additional material was selected and whether the original selection procedure itself was questioned.
That level of description allows another reader to judge whether the investigation narrowed the possible causes. The goal is a supported explanation, even when that explanation remains incomplete, rather than a larger pile of unconnected test numbers.
Sources and further detail
- FDA — Investigating Out-of-Specification Test Results for Pharmaceutical Production (opens in a new tab)
May 2022 revision 1, section IV.B read for retesting, resampling and treatment of original results. Applied examples are original; no Novum testing procedure or regulatory status is asserted.
Sources checked 19 September 2026. Worked examples are illustrative unless a supplied report is explicitly identified. This article has not undergone independent scientific peer review.